Abstract
The World Health Organization has included different types of lymphoma under the aggressive category. In the US, diffuse large B-cell lymphoma is the most common aggressive lymphoma and accounts for > 30% of the 55,000 new cases diagnosed annually. Recent advances in the knowledge of the molecular biology have provided an increased understanding of the heterogeneity of non-Hodgkin's lymphoma. New treatments, especially those with the use of monoclonal antibodies, are improving both the survival and the response rate.
Original language | English (US) |
---|---|
Pages (from-to) | 733-748 |
Number of pages | 16 |
Journal | Expert opinion on pharmacotherapy |
Volume | 7 |
Issue number | 6 |
DOIs | |
State | Published - Apr 2006 |
Keywords
- Akt
- Aurora
- BAFF
- CD40
- HDAC
- Hsp-90
- PLK
- TRAIL
- mTOR
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)